Dr. Bendell on the Future of Regorafenib for Patients With CRC

Johanna C. Bendell, MD
Published: Wednesday, Nov 15, 2017



Johanna C. Bendell, MD, medical oncologist, Sarah Cannon Research Institute, discusses the future of regorafenib (Stivarga) for patients with colorectal cancer (CRC).

Further studies need to be done to determine the best dosage for regorafenib because most patients cannot tolerate the current dose, says Bendell.

A current trial conducted by researchers out of Mayo Clinic is comparing the full dosage to a lower dosage to see if tolerability will translate into increased progression-free survival, explains Bendell.


Johanna C. Bendell, MD, medical oncologist, Sarah Cannon Research Institute, discusses the future of regorafenib (Stivarga) for patients with colorectal cancer (CRC).

Further studies need to be done to determine the best dosage for regorafenib because most patients cannot tolerate the current dose, says Bendell.

A current trial conducted by researchers out of Mayo Clinic is comparing the full dosage to a lower dosage to see if tolerability will translate into increased progression-free survival, explains Bendell.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Oncology Briefings™: Overcoming Chronic Iron Overload in Pediatric AML and MDSJun 30, 20181.0
Publication Bottom Border
Border Publication
x